Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8608219 | 0.88 | ALDH1A1 (0.50) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL1513967 | 0.87 | TSHR (0.69) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL19973714 | 0.85 | MAPT (0.62) | TSHRL3MBTL1CYP3A4ALDH1A1LMNA | |
| SCHEMBL975212 | 0.85 | TSHR (0.77) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL14125177 | 0.85 | LMNA (0.44) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| Methyl Alcohol SCHEMBL27495118 | 0.84 | TSHR (0.70) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL976078 | 0.83 | TSHR (0.75) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL3805742 | 0.83 | TSHR (0.78) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL974445 | 0.83 | TSHR (0.75) | TSHRTDP1L3MBTL1CYP3A4TP53 | |
| SCHEMBL10812457 | 0.83 | TSHR (0.54) | TSHRTDP1L3MBTL1CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448741-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2024-10-23 | — | — | EP | claimed |
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| WO-2021257843-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | AZURRX BIOPHARMA, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | claimed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | claimed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | claimed |
| US-20180344646-A1 | AMORPHOUS DISPERSION GRANULES AND ORAL DOSAGE FORMS | PATHEON DEVELOPMENT SERVICES INC. (US) | 2018-12-06 | — | — | US | claimed |
| EP-1263433-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| EP-1239835-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-20020006443-A1 | Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form | BEND RESEARCH, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | TSHR 4205/4885TDP1 2731/4885L3MBTL1 2184/4885 |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | TSHR 4570/4885TDP1 1490/4885L3MBTL1 3379/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | TSHR 4205/4885TDP1 2731/4885L3MBTL1 2184/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | TSHR 4605/4885TDP1 467/4885L3MBTL1 3804/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | TSHR 4671/4885TDP1 334/4885L3MBTL1 4664/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | TSHR 4205/4885TDP1 2731/4885L3MBTL1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.